In-Jin Jang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
In-Jin Jang has a total of 401 co-authors. Here are the top co-authors by number of shared publications:
- Kyung-Sang Yu
Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul 03080, Republic of Korea
39 shared publications - SeungHwan Lee
Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital Seoul Republic of Korea
35 shared publications - Joo-Youn Cho
Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital Seoul Republic of Korea
34 shared publications Kyung-Sang Yu
Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
18 shared publications- Jaeseong Oh
Department of Pharmacology, Jeju National University College of Medicine, Jeju, Republic of Korea
17 shared publications Sang-Goo Shin
Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea
16 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-15
First-in-Human Phase 1 Evaluation of the DegradaBALL Mesoporous Silica Nanoparticle Delivery System: An mRNA SARS-CoV-2 Vaccine Study in Healthy Korean Adult Volunteers
Purpose: mRNA vaccines require an effective delivery system for intracellular uptake, and alternative carriers with improved stability and tolerability remain of continued interest. This study evaluated the safety, tolerability, and exploratory immunogenicity of LEM-mR203, an mRNA SARS-CoV-2 receptor binding domain (RBD) booster vaccine formulated with DegradaBALL, a mesoporous silica nanoparticle-based delivery system developed to improve mRNA stability and enable localized delivery. Methods: In a randomized, double-blind, placebo-controlled, dose-escalation phase 1 study, a single intramuscular dose of LEM-mR203 (40 μg or 100 μg) or placebo was administered to 20 healthy Korean adult volunteers. Safety endpoints included solicited and unsolicited adverse events (AEs), serious AEs, and AEs of special interest. Exploratory immunogenicity comprised anti-RBD antibody concentrations and neutralizing antibody (Nab) titers through Day 366, together with interferon-γ (IFN-γ)/interleukin-4 (IL-4) ELISpot responses. Results: LEM-mR203 was well tolerated at both dose levels, with mild (Grade 1) injection-site reactions and infrequent solicited systemic AEs; no fever, serious AEs, or AEs of special interest were reported. Transient, asymptomatic decreases in white blood cell count occurred across active and placebo groups and resolved without sequelae. In this pre-immune cohort (85% anti-nucleocapsid reactive), anti-RBD IgG was maintained through Day 366 without a clear booster-induced increase and Nab titers against the Kappa variant (B.1.617.1) waned, consistent with known mRNA vaccine kinetics. Exploratory ELISpot results suggested an IFN-γ-oriented cellular response in the 100 μg group, without evidence of IL-4/Th2 skewing. Conclusion: A single booster dose of LEM-mR203 was well tolerated, with no major safety concerns over 366 days, and with exploratory cellular responses suggesting an IFN-γ-oriented profile without Th2 skewing. Given the small sample size and high pre-existing immunity, these findings require confirmation in larger, adequately powered studies of DegradaBALL-based mRNA vaccines.
- 1 October 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-15
Open AccessFirst-in-Human Phase 1 Evaluation of the DegradaBALL Mesoporous Silica Nanoparticle Delivery System: An mRNA SARS-CoV-2 Vaccine Study in Healthy Korean Adult Volunteers
Purpose: mRNA vaccines require an effective delivery system for intracellular uptake, and alternative carriers with improved stability and tolerability remain of continued interest. This study evaluated the safety, tolerability, and exploratory immunogenicity of LEM-mR203, an mRNA SARS-CoV-2 receptor binding domain (RBD) booster vaccine formulated with DegradaBALL, a mesoporous silica nanoparticle-based delivery system developed to improve mRNA stability and enable localized delivery. Methods: In a randomized, double-blind, placebo-controlled, dose-escalation phase 1 study, a single intramuscular dose of LEM-mR203 (40 μg or 100 μg) or placebo was administered to 20 healthy Korean adult volunteers. Safety endpoints included solicited and unsolicited adverse events (AEs), serious AEs, and AEs of special interest. Exploratory immunogenicity comprised anti-RBD antibody concentrations and neutralizing antibody (Nab) titers through Day 366, together with interferon-γ (IFN-γ)/interleukin-4 (IL-4) ELISpot responses. Results: LEM-mR203 was well tolerated at both dose levels, with mild (Grade 1) injection-site reactions and infrequent solicited systemic AEs; no fever, serious AEs, or AEs of special interest were reported. Transient, asymptomatic decreases in white blood cell count occurred across active and placebo groups and resolved without sequelae. In this pre-immune cohort (85% anti-nucleocapsid reactive), anti-RBD IgG was maintained through Day 366 without a clear booster-induced increase and Nab titers against the Kappa variant (B.1.617.1) waned, consistent with known mRNA vaccine kinetics. Exploratory ELISpot results suggested an IFN-γ-oriented cellular response in the 100 μg group, without evidence of IL-4/Th2 skewing. Conclusion: A single booster dose of LEM-mR203 was well tolerated, with no major safety concerns over 366 days, and with exploratory cellular responses suggesting an IFN-γ-oriented profile without Th2 skewing. Given the small sample size and high pre-existing immunity, these findings require confirmation in larger, adequately powered studies of DegradaBALL-based mRNA vaccines.
- Open Access
- 25 August 2026
- Published by Elsevier in SSRN Electronic Journal
Impact of Gastrectomy on the Pharmacokinetics of First-Line Anti-tuberculosis Drugs in Tuberculosis Patients: A Prospective Cohort Study
Background Gastrectomy can alter oral drug absorption, but its effect on first-line antituberculosis drug pharmacokinetics is poorly characterised. We aimed to evaluate the effect of gastrectomy on the pharmacokinetics of these drugs.Methods Twenty patients with active tuberculosis and a history of gastrectomy and 20 patients without previous gastrointestinal surgery were enrolled at the National Cancer Center, Republic of Korea, between June 2010 and December 2018. At least 1 month after initiation of standard first-line antituberculosis therapy, serial plasma samples were collected for pharmacokinetic analysis. The primary pharmacokinetic outcome was the area under the plasma concentration-time curve from time zero to the last measurable concentration (AUCₗₐₛₜ) for each drug.Findings The gastrectomy and control groups were comparable in baseline demographics (median age, 58 vs 60 years; height, 1.66 vs 1.63 m; bodyweight, 55.3 vs 59.0 kg; all P>0.05). Plasma exposure to rifampicin and pyrazinamide was significantly lower in the gastrectomy group than in the control group. The mean (SD) AUCₗₐₛₜ values were 29.9 (13.7) vs 58.6 (28.2) mg·h/L for rifampicin (GMR 0.49, 90% CI 0.37–0.67; p<0.001) and 149.6 (49.5) vs 197.4 (58.8) mg·h/L for pyrazinamide (GMR 0.76, 90% CI 0.62–0.93; p<0.05). The median Tₘₐₓ of rifampicin was significantly longer in the gastrectomy group than in the control group (4 vs 2 h; p<0.05). No significant pharmacokinetic differences were observed for isoniazid or ethambutol. Treatment was extended in five (25%) patients in the gastrectomy group and three (15%) controls; delayed treatment response occurred in five (25%) and two (10%) patients, respectively.Interpretation Gastrectomised patients had lower plasma exposure to rifampicin and pyrazinamide and delayed rifampicin absorption. Altered antituberculosis drug exposure should be considered in patients with previous gastrectomy, particularly when treatment response is delayed. FundingThis work was supported by National Cancer Center Grant 1610120.
- 25 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImpact of Gastrectomy on the Pharmacokinetics of First-Line Anti-tuberculosis Drugs in Tuberculosis Patients: A Prospective Cohort Study
Background Gastrectomy can alter oral drug absorption, but its effect on first-line antituberculosis drug pharmacokinetics is poorly characterised. We aimed to evaluate the effect of gastrectomy on the pharmacokinetics of these drugs.Methods Twenty patients with active tuberculosis and a history of gastrectomy and 20 patients without previous gastrointestinal surgery were enrolled at the National Cancer Center, Republic of Korea, between June 2010 and December 2018. At least 1 month after initiation of standard first-line antituberculosis therapy, serial plasma samples were collected for pharmacokinetic analysis. The primary pharmacokinetic outcome was the area under the plasma concentration-time curve from time zero to the last measurable concentration (AUCₗₐₛₜ) for each drug.Findings The gastrectomy and control groups were comparable in baseline demographics (median age, 58 vs 60 years; height, 1.66 vs 1.63 m; bodyweight, 55.3 vs 59.0 kg; all P>0.05). Plasma exposure to rifampicin and pyrazinamide was significantly lower in the gastrectomy group than in the control group. The mean (SD) AUCₗₐₛₜ values were 29.9 (13.7) vs 58.6 (28.2) mg·h/L for rifampicin (GMR 0.49, 90% CI 0.37–0.67; p<0.001) and 149.6 (49.5) vs 197.4 (58.8) mg·h/L for pyrazinamide (GMR 0.76, 90% CI 0.62–0.93; p<0.05). The median Tₘₐₓ of rifampicin was significantly longer in the gastrectomy group than in the control group (4 vs 2 h; p<0.05). No significant pharmacokinetic differences were observed for isoniazid or ethambutol. Treatment was extended in five (25%) patients in the gastrectomy group and three (15%) controls; delayed treatment response occurred in five (25%) and two (10%) patients, respectively.Interpretation Gastrectomised patients had lower plasma exposure to rifampicin and pyrazinamide and delayed rifampicin absorption. Altered antituberculosis drug exposure should be considered in patients with previous gastrectomy, particularly when treatment response is delayed. FundingThis work was supported by National Cancer Center Grant 1610120.
- Open Access
- 1 April 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-11
Safety and Pharmacokinetics of SRN001, a Novel siRNA Drug Targeting Amphiregulin via the SAMiRNA Platform
SRN001 is a small interfering RNA (siRNA) drug targeting amphiregulin. It was developed using a novel SAMiRNA® platform, in which the siRNAs are protected within a self-assembled micelle. This platform eliminates the need for additional excipients to reduce unintended immune reactions. Amphiregulin plays a critical role in tissue repair and immune modulation. By silencing it, SRN001 is expected to be a therapeutic option for various pathologically fibrotic and cancerous diseases. This study aimed to evaluate safety and pharmacokinetics (PK) of SRN001 in humans for the first time. A randomized, double-blind, placebo-controlled, single ascending dose, Phase 1 trial was conducted (NCT05984992). Participants randomly received a single intravenous dose of SRN001 (15, 45, 135, or 210 mg) or placebo. Safety was assessed with vital signs, clinical laboratory tests, electrocardiograms, and inflammatory cytokine assays (IL-1β, IL-6, IFN-γ, and TNF-α). Serial blood samples were collected until 168 hours post-dose to quantify plasma antisense siRNA concentrations. Anti-drug antibodies (ADAs) were measured at pre-dose, 15 days, and 29 days post-dose. Among 25 participants, SRN001 was generally well tolerated. Unlike other approved siRNA drugs, no systemic symptoms or cytokine elevation suggestive of infusion-related reactions (IRRs) were observed in any subjects receiving SRN001, even without premedication. SRN001 exhibited dose-proportional exposure, with the average AUCinf of 1.35 ug·hour/mL in the 15 mg dose group, achieving the therapeutic exposure in preclinical studies. The average plasma half-life was 0.48 hours. No ADAs were detected. A single IV administration of SRN001 demonstrated a favorable safety profile and dose-proportional PK in this small first-in-human phase 1 clinical trial. By minimizing the need for excipients, the SAMiRNA platform is anticipated to facilitate the development of safer siRNA drugs in the future. Therapeutic potential of SRN001 will be explored in subsequent clinical trials.
- 1 April 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-11
Open AccessSafety and Pharmacokinetics of SRN001, a Novel siRNA Drug Targeting Amphiregulin via the SAMiRNA Platform
SRN001 is a small interfering RNA (siRNA) drug targeting amphiregulin. It was developed using a novel SAMiRNA® platform, in which the siRNAs are protected within a self-assembled micelle. This platform eliminates the need for additional excipients to reduce unintended immune reactions. Amphiregulin plays a critical role in tissue repair and immune modulation. By silencing it, SRN001 is expected to be a therapeutic option for various pathologically fibrotic and cancerous diseases. This study aimed to evaluate safety and pharmacokinetics (PK) of SRN001 in humans for the first time. A randomized, double-blind, placebo-controlled, single ascending dose, Phase 1 trial was conducted (NCT05984992). Participants randomly received a single intravenous dose of SRN001 (15, 45, 135, or 210 mg) or placebo. Safety was assessed with vital signs, clinical laboratory tests, electrocardiograms, and inflammatory cytokine assays (IL-1β, IL-6, IFN-γ, and TNF-α). Serial blood samples were collected until 168 hours post-dose to quantify plasma antisense siRNA concentrations. Anti-drug antibodies (ADAs) were measured at pre-dose, 15 days, and 29 days post-dose. Among 25 participants, SRN001 was generally well tolerated. Unlike other approved siRNA drugs, no systemic symptoms or cytokine elevation suggestive of infusion-related reactions (IRRs) were observed in any subjects receiving SRN001, even without premedication. SRN001 exhibited dose-proportional exposure, with the average AUCinf of 1.35 ug·hour/mL in the 15 mg dose group, achieving the therapeutic exposure in preclinical studies. The average plasma half-life was 0.48 hours. No ADAs were detected. A single IV administration of SRN001 demonstrated a favorable safety profile and dose-proportional PK in this small first-in-human phase 1 clinical trial. By minimizing the need for excipients, the SAMiRNA platform is anticipated to facilitate the development of safer siRNA drugs in the future. Therapeutic potential of SRN001 will be explored in subsequent clinical trials.
- Open Access
- 1 March 2026
- Vol. 15 (3) , e70208
Population Pharmacokinetic-Pharmacodynamic Analysis of Zolpidem in Healthy Volunteers: Covariate Contributions to Variability in CNS Responses.
Population pharmacokinetic-pharmacodynamic (PK-PD) modeling was used to explore covariate effects on zolpidem PKs and PDs in 30 healthy Korean volunteers (15 males, 15 females) who received a single 10 mg dose. The dataset included 325 PK observations and 388 observations each for the digit symbol substitution test (DSST), choice reaction time (CRT), and visual analog scale (VAS). A one-compartment PK model with transit compartment absorption and first-order elimination was developed, followed by sequential sigmoid Emax-based direct response models for each PD endpoint. A hyperbolic learning effect model was incorporated for DSST, whereas CRT showed no clear learning effect. Baseline VAS was described using linear splines. No clinically meaningful covariates were retained in the final PK or PK-VAS models. In contrast, higher body weight was associated with reduced DSST IC50 and CRT EC50. Lower albumin was associated with increased potency for both DSST and CRT and with a steeper concentration-response relationship for CRT. Higher baseline CRT values were linked to greater potency and a steeper slope for CRT, and older age was associated with lower baseline DSST and CRT performance. These exploratory findings suggest that variability in zolpidem response may be partially mediated by physiologically and functionally relevant factors, such as body weight, albumin, age, and baseline PD measures, which could complement sex in individualized risk assessment.
- 1 March 2026
- Vol. 15 (3) , e70208
Open AccessPopulation Pharmacokinetic-Pharmacodynamic Analysis of Zolpidem in Healthy Volunteers: Covariate Contributions to Variability in CNS Responses.
Population pharmacokinetic-pharmacodynamic (PK-PD) modeling was used to explore covariate effects on zolpidem PKs and PDs in 30 healthy Korean volunteers (15 males, 15 females) who received a single 10 mg dose. The dataset included 325 PK observations and 388 observations each for the digit symbol substitution test (DSST), choice reaction time (CRT), and visual analog scale (VAS). A one-compartment PK model with transit compartment absorption and first-order elimination was developed, followed by sequential sigmoid Emax-based direct response models for each PD endpoint. A hyperbolic learning effect model was incorporated for DSST, whereas CRT showed no clear learning effect. Baseline VAS was described using linear splines. No clinically meaningful covariates were retained in the final PK or PK-VAS models. In contrast, higher body weight was associated with reduced DSST IC50 and CRT EC50. Lower albumin was associated with increased potency for both DSST and CRT and with a steeper concentration-response relationship for CRT. Higher baseline CRT values were linked to greater potency and a steeper slope for CRT, and older age was associated with lower baseline DSST and CRT performance. These exploratory findings suggest that variability in zolpidem response may be partially mediated by physiologically and functionally relevant factors, such as body weight, albumin, age, and baseline PD measures, which could complement sex in individualized risk assessment.
- Open Access
- 26 February 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (3)
Population Pharmacokinetic–Pharmacodynamic Analysis of Zolpidem in Healthy Volunteers: Covariate Contributions to Variability in CNS Responses
Population pharmacokinetic–pharmacodynamic (PK–PD) modeling was used to explore covariate effects on zolpidem PKs and PDs in 30 healthy Korean volunteers (15 males, 15 females) who received a single 10 mg dose. The dataset included 325 PK observations and 388 observations each for the digit symbol substitution test (DSST), choice reaction time (CRT), and visual analog scale (VAS). A one‐compartment PK model with transit compartment absorption and first‐order elimination was developed, followed by sequential sigmoid E max ‐based direct response models for each PD endpoint. A hyperbolic learning effect model was incorporated for DSST, whereas CRT showed no clear learning effect. Baseline VAS was described using linear splines. No clinically meaningful covariates were retained in the final PK or PK–VAS models. In contrast, higher body weight was associated with reduced DSST IC 50 and CRT EC 50 . Lower albumin was associated with increased potency for both DSST and CRT and with a steeper concentration‐response relationship for CRT. Higher baseline CRT values were linked to greater potency and a steeper slope for CRT, and older age was associated with lower baseline DSST and CRT performance. These exploratory findings suggest that variability in zolpidem response may be partially mediated by physiologically and functionally relevant factors, such as body weight, albumin, age, and baseline PD measures, which could complement sex in individualized risk assessment.
- 26 February 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (3)
Open AccessPopulation Pharmacokinetic–Pharmacodynamic Analysis of Zolpidem in Healthy Volunteers: Covariate Contributions to Variability in CNS Responses
Population pharmacokinetic–pharmacodynamic (PK–PD) modeling was used to explore covariate effects on zolpidem PKs and PDs in 30 healthy Korean volunteers (15 males, 15 females) who received a single 10 mg dose. The dataset included 325 PK observations and 388 observations each for the digit symbol substitution test (DSST), choice reaction time (CRT), and visual analog scale (VAS). A one‐compartment PK model with transit compartment absorption and first‐order elimination was developed, followed by sequential sigmoid E max ‐based direct response models for each PD endpoint. A hyperbolic learning effect model was incorporated for DSST, whereas CRT showed no clear learning effect. Baseline VAS was described using linear splines. No clinically meaningful covariates were retained in the final PK or PK–VAS models. In contrast, higher body weight was associated with reduced DSST IC 50 and CRT EC 50 . Lower albumin was associated with increased potency for both DSST and CRT and with a steeper concentration‐response relationship for CRT. Higher baseline CRT values were linked to greater potency and a steeper slope for CRT, and older age was associated with lower baseline DSST and CRT performance. These exploratory findings suggest that variability in zolpidem response may be partially mediated by physiologically and functionally relevant factors, such as body weight, albumin, age, and baseline PD measures, which could complement sex in individualized risk assessment.
- Open Access
- 1 January 2026
- Published by XMLink in Translational and Clinical Pharmacology
- Vol. 34 (2) , 88-99
Pharmacokinetics and safety of nafamostat and its metabolites following single- and multiple-dose oral administration of nafamostat mesylate in healthy male participants
Hong JK, et al. Transl Clin Pharmacol. 2026 Jun;34(2):88-99. https://doi.org/10.12793/tcp.2026.34.e7
- 1 January 2026
- Published by XMLink in Translational and Clinical Pharmacology
- Vol. 34 (2) , 88-99
Open AccessPharmacokinetics and safety of nafamostat and its metabolites following single- and multiple-dose oral administration of nafamostat mesylate in healthy male participants
Hong JK, et al. Transl Clin Pharmacol. 2026 Jun;34(2):88-99. https://doi.org/10.12793/tcp.2026.34.e7
- Open Access
- 14 October 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (3) , 860-868
Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects
Aims: Vutiglabridin (HSG4112) is a novel drug under clinical development for antiobesity treatment. This study aimed to evaluate the pharmacokinetics (PKs) and safety of vutiglabridin after multiple oral administrations in healthy Korean female and obese subjects and explore short‐term pharmacodynamic (PD) responses. Methods: Two separate randomized, double‐blind, placebo‐controlled studies were conducted in healthy female and obese subjects. The subjects in each dose group (480 or 720 mg) received vutiglabridin or placebo once daily for 14 days under fed conditions at an 8:2 ratio. Serial blood samples were collected on days 1 and 14 for PK analysis. PD biomarkers related to obesity and inflammation were assessed, and safety and tolerability were evaluated throughout the study. Results: At steady state, obese subjects exhibited a 9%–13% higher maximum concentration (C max,ss ) and a 17%–19% lower area under the plasma concentration–time curve for a dosing interval at steady state (AUC τ,ss ). This profile reflects altered absorption and distribution due to obesity‐related physiological changes. After 14 days of treatment, compared with healthy females, obese subjects had greater decreases in baseline‐corrected body weights in the 480 mg, 720 mg and placebo groups. Vutiglabridin was safe and well tolerated in both groups. Conclusions: Vutiglabridin presented higher peak plasma concentrations but lower systemic exposure in obese subjects than in healthy females. Additionally, a modest downward trend in body weight was observed in obese subjects relative to healthy female subjects. These findings support further long‐term phase II clinical trials.
- 14 October 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (3) , 860-868
Open AccessPharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects
Aims: Vutiglabridin (HSG4112) is a novel drug under clinical development for antiobesity treatment. This study aimed to evaluate the pharmacokinetics (PKs) and safety of vutiglabridin after multiple oral administrations in healthy Korean female and obese subjects and explore short‐term pharmacodynamic (PD) responses. Methods: Two separate randomized, double‐blind, placebo‐controlled studies were conducted in healthy female and obese subjects. The subjects in each dose group (480 or 720 mg) received vutiglabridin or placebo once daily for 14 days under fed conditions at an 8:2 ratio. Serial blood samples were collected on days 1 and 14 for PK analysis. PD biomarkers related to obesity and inflammation were assessed, and safety and tolerability were evaluated throughout the study. Results: At steady state, obese subjects exhibited a 9%–13% higher maximum concentration (C max,ss ) and a 17%–19% lower area under the plasma concentration–time curve for a dosing interval at steady state (AUC τ,ss ). This profile reflects altered absorption and distribution due to obesity‐related physiological changes. After 14 days of treatment, compared with healthy females, obese subjects had greater decreases in baseline‐corrected body weights in the 480 mg, 720 mg and placebo groups. Vutiglabridin was safe and well tolerated in both groups. Conclusions: Vutiglabridin presented higher peak plasma concentrations but lower systemic exposure in obese subjects than in healthy females. Additionally, a modest downward trend in body weight was observed in obese subjects relative to healthy female subjects. These findings support further long‐term phase II clinical trials.
- Open Access
- 1 September 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 7853-7863
Population Pharmacokinetic and Pharmacodynamic Modeling of Enteric-Coated Aspirin Capsule and Tablet Formulations in Healthy Subjects
Purpose: This study aimed to develop a population pharmacokinetic-pharmacodynamic (PK-PD) model to predict the PKs of acetylsalicylic acid (ASA) and salicylic acid (SA), and their effects on thromboxane B2 (TXB2) inhibition following oral administration of two enteric-coated aspirin formulations. Patients and Methods: Data from two Phase I studies in healthy Korean subjects were used to develop the PK-PD model. A nonlinear mixed effect modeling approach was implemented using Monolix®, based on 669 plasma concentrations of ASA and SA and 83 serum TXB2 concentrations from 44 subjects. Simulx® was used for model-based simulation and external validation using published literature data. Differences in absorption profiles between two formulations were assessed as a covariate effect. Results: The PK of aspirin was well described by a one-compartment model for ASA and a two-compartment model for SA, incorporating pre-systemic metabolism and dual absorption. A turnover model with an Emax function captured the TXB2 inhibition. The capsule formulation showed faster absorption (0.22 h− 1) than the tablet (0.053 h− 1), but this did not affect TXB2 inhibition. Body weight significantly influenced ASA-to-SA metabolism and SA clearance. External validation confirmed that the model adequately predicted PK and PD profiles at both 80 mg and 160 mg doses, with simulated TXB2 inhibition showing similar responses between formulations at steady state, exceeding 80%. Conclusion: This model adequately described the PK and PD of enteric-coated aspirin and demonstrated comparable TXB2 inhibition between the capsule and tablet formulations, supporting their potential interchangeability in clinical practice.
- 1 September 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 7853-7863
Open AccessPopulation Pharmacokinetic and Pharmacodynamic Modeling of Enteric-Coated Aspirin Capsule and Tablet Formulations in Healthy Subjects
Purpose: This study aimed to develop a population pharmacokinetic-pharmacodynamic (PK-PD) model to predict the PKs of acetylsalicylic acid (ASA) and salicylic acid (SA), and their effects on thromboxane B2 (TXB2) inhibition following oral administration of two enteric-coated aspirin formulations. Patients and Methods: Data from two Phase I studies in healthy Korean subjects were used to develop the PK-PD model. A nonlinear mixed effect modeling approach was implemented using Monolix®, based on 669 plasma concentrations of ASA and SA and 83 serum TXB2 concentrations from 44 subjects. Simulx® was used for model-based simulation and external validation using published literature data. Differences in absorption profiles between two formulations were assessed as a covariate effect. Results: The PK of aspirin was well described by a one-compartment model for ASA and a two-compartment model for SA, incorporating pre-systemic metabolism and dual absorption. A turnover model with an Emax function captured the TXB2 inhibition. The capsule formulation showed faster absorption (0.22 h− 1) than the tablet (0.053 h− 1), but this did not affect TXB2 inhibition. Body weight significantly influenced ASA-to-SA metabolism and SA clearance. External validation confirmed that the model adequately predicted PK and PD profiles at both 80 mg and 160 mg doses, with simulated TXB2 inhibition showing similar responses between formulations at steady state, exceeding 80%. Conclusion: This model adequately described the PK and PD of enteric-coated aspirin and demonstrated comparable TXB2 inhibition between the capsule and tablet formulations, supporting their potential interchangeability in clinical practice.
- Open Access
- 4 August 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (10) , 1682-1694
Model‐Informed Precision Dosing of Infliximab in Korean Inflammatory Bowel Disease Patients: External Validation of Population Pharmacokinetic Models
Underexposure to infliximab often leads to loss of response in patients with inflammatory bowel disease (IBD). Model‐informed precision dosing (MIPD) offers a superior approach to maintaining target infliximab concentrations compared to empirical dosage adjustment. This study aims to externally validate the population pharmacokinetic (PK) models implemented in TDMx, an online MIPD dashboard system, for adult and pediatric Korean IBD patients before clinical use. This retrospective study included 199 IBD patients (142 adults, 57 children) treated with intravenous infliximab at Seoul National University Hospital (Seoul, Republic of Korea) from 2019 to 2023. Three adult and seven pediatric models were evaluated based on accuracy, precision, goodness of fit plots, prediction‐corrected visual predictive checks, and normalized prediction distribution errors. For adults, the Passot model showed the best fit (mean percentage error (MPE) 26.4%, mean absolute error (MAE) 1.1 mg/L, relative root‐mean square error (rRMSE) 159.0%), whereas all pediatric models were unsuitable for clinical use (MPE 30.4%–143.4%, MAE 1.4–2.6 mg/L, rRMSE 96.3%–564.0%). Predictive performance was compared between datasets with or without accurate information on antibodies‐toward‐infliximab (ATI), as well as with and without previous concentrations. Assuming all patients were ATI positive improved predictive performance, likely due to the inherent positive bias of the population PK models. Incorporating previous concentrations improved predictions for adult models, achieving acceptable accuracy and precision (Passot model: MPE 17.5%, MAE 1.8 mg/L, rRMSE 80.3% with one concentration). However, pediatric models remained clinically unacceptable, highlighting the need to develop models specifically tailored for this population.
- 4 August 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (10) , 1682-1694
Open AccessModel‐Informed Precision Dosing of Infliximab in Korean Inflammatory Bowel Disease Patients: External Validation of Population Pharmacokinetic Models
Underexposure to infliximab often leads to loss of response in patients with inflammatory bowel disease (IBD). Model‐informed precision dosing (MIPD) offers a superior approach to maintaining target infliximab concentrations compared to empirical dosage adjustment. This study aims to externally validate the population pharmacokinetic (PK) models implemented in TDMx, an online MIPD dashboard system, for adult and pediatric Korean IBD patients before clinical use. This retrospective study included 199 IBD patients (142 adults, 57 children) treated with intravenous infliximab at Seoul National University Hospital (Seoul, Republic of Korea) from 2019 to 2023. Three adult and seven pediatric models were evaluated based on accuracy, precision, goodness of fit plots, prediction‐corrected visual predictive checks, and normalized prediction distribution errors. For adults, the Passot model showed the best fit (mean percentage error (MPE) 26.4%, mean absolute error (MAE) 1.1 mg/L, relative root‐mean square error (rRMSE) 159.0%), whereas all pediatric models were unsuitable for clinical use (MPE 30.4%–143.4%, MAE 1.4–2.6 mg/L, rRMSE 96.3%–564.0%). Predictive performance was compared between datasets with or without accurate information on antibodies‐toward‐infliximab (ATI), as well as with and without previous concentrations. Assuming all patients were ATI positive improved predictive performance, likely due to the inherent positive bias of the population PK models. Incorporating previous concentrations improved predictions for adult models, achieving acceptable accuracy and precision (Passot model: MPE 17.5%, MAE 1.8 mg/L, rRMSE 80.3% with one concentration). However, pediatric models remained clinically unacceptable, highlighting the need to develop models specifically tailored for this population.
- Open Access
- 31 May 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Saliva-based lacosamide monitoring paves the way toward personalized epilepsy pharmacotherapy
Saliva, known for better patient compliance and simpler collection, is ideal for monitoring antiseizure medication (ASM) levels. This study aimed to validate saliva for measuring lacosamide, develop a pharmacokinetic (PK) model, and determine the optimal saliva concentration for seizure control in epilepsy patients. In our prospective study at Seoul National University Hospital from August 2021 to November 2022, we enrolled lacosamide-prescribed epilepsy patients, collecting their saliva and blood samples. We developed a population PK model with nonlinear mixed-effects modeling, incorporating a saliva compartment and plasma-to-saliva distribution scaling factor. The model, factoring in CYP2C19 genotypes, demographics, and concurrent ASM use, estimated optimal saliva lacosamide concentration cutoffs for well-controlled seizures in high seizure burden patients. These values were validated through a two-year longitudinal analysis. In our study, 123 epilepsy patients prescribed lacosamide were finally analyzed. We identified 74 matched pairs of blood and saliva samples, finding a linear relationship between their lacosamide concentrations (R = 0.62, P < 0.001). Using our PK model, we estimated individual peak (Cmax) and trough concentrations in saliva and blood based on dosage, determining optimal saliva cutoffs for well-controlled seizure status in lacosamide: 15.94 mg/L for Cmax and 9.056 mg/L for trough, with 72.7% sensitivity and 88.2% specificity. Longitudinal analysis showed well-controlled seizure status achievement aligning with times when estimated Cmax and trough surpassed these cutoffs. Our research presents the potential and validity of using saliva concentration as an alternative to blood concentration for lacosamide TDM, advancing personalized pharmacotherapy in epilepsy treatment.
- 31 May 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Open AccessSaliva-based lacosamide monitoring paves the way toward personalized epilepsy pharmacotherapy
Saliva, known for better patient compliance and simpler collection, is ideal for monitoring antiseizure medication (ASM) levels. This study aimed to validate saliva for measuring lacosamide, develop a pharmacokinetic (PK) model, and determine the optimal saliva concentration for seizure control in epilepsy patients. In our prospective study at Seoul National University Hospital from August 2021 to November 2022, we enrolled lacosamide-prescribed epilepsy patients, collecting their saliva and blood samples. We developed a population PK model with nonlinear mixed-effects modeling, incorporating a saliva compartment and plasma-to-saliva distribution scaling factor. The model, factoring in CYP2C19 genotypes, demographics, and concurrent ASM use, estimated optimal saliva lacosamide concentration cutoffs for well-controlled seizures in high seizure burden patients. These values were validated through a two-year longitudinal analysis. In our study, 123 epilepsy patients prescribed lacosamide were finally analyzed. We identified 74 matched pairs of blood and saliva samples, finding a linear relationship between their lacosamide concentrations (R = 0.62, P < 0.001). Using our PK model, we estimated individual peak (Cmax) and trough concentrations in saliva and blood based on dosage, determining optimal saliva cutoffs for well-controlled seizure status in lacosamide: 15.94 mg/L for Cmax and 9.056 mg/L for trough, with 72.7% sensitivity and 88.2% specificity. Longitudinal analysis showed well-controlled seizure status achievement aligning with times when estimated Cmax and trough surpassed these cutoffs. Our research presents the potential and validity of using saliva concentration as an alternative to blood concentration for lacosamide TDM, advancing personalized pharmacotherapy in epilepsy treatment.